2869 Participants Needed

Human-Centered Intervention for Lung Cancer Screening

(ELFE Trial)

LR
NS
Overseen ByNeha Singh, B.S
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, Davis
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The purpose of this study is to further understand the factors involved in increasing lung cancer screening.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Pre-Visit Planner, Pre-Visit Planner + MyChart for lung cancer screening?

The use of decision aids (tools to help patients make informed choices) in lung cancer screening has been shown to reduce patient uncertainty and improve understanding of screening benefits and risks. This suggests that similar tools, like the Pre-Visit Planner and MyChart, could help patients better understand and engage with their lung cancer screening process.12345

Is the Human-Centered Intervention for Lung Cancer Screening safe for humans?

The research does not provide specific safety data for the Human-Centered Intervention for Lung Cancer Screening, but it does mention that lung cancer screening with low-dose computed tomography generally has few major complications, although there are potential harms like false-positive results and procedural complications.678910

How does the Human-Centered Intervention for Lung Cancer Screening differ from other treatments for lung cancer?

The Human-Centered Intervention for Lung Cancer Screening is unique because it focuses on addressing the barriers to implementing lung cancer screening programs, such as patient-provider communication and logistical challenges, rather than being a direct medical treatment. This approach emphasizes individualized risk assessment, shared decision-making, and a multidisciplinary strategy to improve the effectiveness and accessibility of lung cancer screening.811121314

Eligibility Criteria

This trial is for patients aged 50-80 who are eligible for lung cancer screening, have a history of smoking, and receive care at specified UCDH clinics. It's also for UCDH primary care providers and staff. People under 49, non-UCDH staff, those already screened for lung cancer, non-consenting individuals or those not fluent in English or Spanish, and patients with existing cancer cannot join.

Inclusion Criteria

Patients who are eligible for lung cancer screening
I am a healthcare provider at UCDHS serving patients aged 50-80.
I am between 50-80 years old, have a history of smoking, and receive care at a specified UCDH clinic.

Exclusion Criteria

I am 49 years old or younger.
Non UCDHS primary care providers and clinic staff
UCDHS patients who have already received Lung Cancer Screening
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive a human-centered intervention to increase lung cancer screening, including verification of smoking history and educational video

156 weeks

Follow-up

Participants are monitored for the effectiveness of the intervention in increasing lung cancer screening

156 weeks

Treatment Details

Interventions

  • Pre-Visit Planner
  • Pre-Visit Planner + MyChart
Trial Overview The study aims to understand how to improve lung cancer screening rates by testing two approaches: a 'Pre-Visit Planner' tool alone versus the planner combined with 'MyChart', an electronic health record system. The effectiveness of these interventions in increasing screenings will be compared.
Participant Groups
3Treatment groups
Experimental Treatment
Active Control
Group I: Pre-Visit Planner (PVP) + MyChartExperimental Treatment1 Intervention
A Licensed Vocational Nurse (LVN) will verify patient smoking history and calculate pack years with the patient over the phone. In addition, the patient will receive educational video through MyChart prior to an LVN calling.
Group II: Pre-Visit Planner (PVP)Experimental Treatment1 Intervention
A Licensed Vocational Nurse (LVN) will verify patient smoking history and calculate pack years with the patient over the phone.
Group III: Usual CareActive Control1 Intervention
Patients will receive usual care.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Davis

Lead Sponsor

Trials
958
Recruited
4,816,000+

Findings from Research

A single-page, paper-based encounter decision aid (EDA) used during shared decision-making visits for lung cancer screening significantly reduced patient decisional conflict, as indicated by a drop in the Decisional Conflict Scale score from 35.0 to 0.2 (p < 0.001).
While 28% of patients understood the mortality benefit of lung cancer screening after the visit, a much higher percentage (82%) grasped the frequency of abnormal screening results, highlighting the need for improved patient education on the mortality benefits of screening.
Pilot Study of an Encounter Decision Aid for Lung Cancer Screening.Ito Fukunaga, M., Balwan, A., Janis, JA., et al.[2023]
In a study of 188 lung cancer screening patients, nearly half (47%) misidentified their follow-up recommendations, indicating a significant gap in patient understanding of screening results, particularly among those with lower education levels and higher Lung-RADS scores.
Despite the high rate of misidentification, incorrect understanding of follow-up recommendations did not correlate with lower adherence to follow-up, suggesting that other factors, such as provider communication, may play a more critical role in ensuring patients follow through with recommended screenings.
Patient Identification of Lung Cancer Screening Follow-Up Recommendations and the Association with Adherence.Triplette, M., Wenger, DS., Shahrir, S., et al.[2022]
In a study of 901 high-risk patients undergoing CT lung cancer screening, 85.7% adhered to radiologist follow-up recommendations, indicating that high adherence rates are achievable in clinical settings.
The main reasons for nonadherence included patient refusal for follow-up exams (66.7%) and difficulties in contacting patients (20.9%), highlighting areas for improvement in patient engagement and communication.
Adherence to Radiology Recommendations in a Clinical CT Lung Screening Program.Alshora, S., McKee, BJ., Regis, SM., et al.[2018]

References

Pilot Study of an Encounter Decision Aid for Lung Cancer Screening. [2023]
Patient Identification of Lung Cancer Screening Follow-Up Recommendations and the Association with Adherence. [2022]
Adherence to Radiology Recommendations in a Clinical CT Lung Screening Program. [2018]
Pulmonary Nodules: A Small Problem for Many, Severe Distress for Some, and How to Communicate About It. [2021]
Understanding lung cancer screening behavior: Racial, gender, and geographic differences among Indiana long-term smokers. [2023]
Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention. [2023]
Lung cancer screening: assessment of health literacy and readability of online educational resources. [2019]
Reviewing Lung Cancer Screening: The Who, Where, When, Why, and How. [2019]
Assessment of Lung Cancer Screening Eligibility on NCI-Designated Cancer Center Websites. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Quantifying Benefits and Harms of Lung Cancer Screening in an Underserved Population: Results From a Prospective Study. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
Multilevel Barriers to the Successful Implementation of Lung Cancer Screening: Why Does It Have to Be So Hard? [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
Development and Psychometric Evaluation of the Lung Cancer Screening Health Belief Scales. [2018]
A qualitative analysis of smokers' perceptions about lung cancer screening. [2018]
14.United Statespubmed.ncbi.nlm.nih.gov
Issues with implementing a high-quality lung cancer screening program. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity